The Year in Cardiology 2013: cardiovascular disease prevention by Gielen, S & Landmesser, U
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
The Year in Cardiology 2013: cardiovascular disease prevention
Gielen, S; Landmesser, U
Abstract: The decline in cardiovascular mortality in Europe by nearly 50% over the last three decades
resulted in particular from improved risk factor control and prevention interventions in addition to im-
proved treatment. This review provides an overview of key studies in epidemiology, hypertension control,
lipidology, diabetology, and lifestyle changes published in 2013. EXAMINE in diabetology and AIM-High
and HPS-2-THRIVE in lipidology failed to demonstrate an event reduction. According to EUROASPIRE
IV clinical implementation of secondary prevention treatments is still suboptimal. The 2013 study high-
lights in prevention prove the dynamic progress of knowledge in the field;, however, knowledge alone is
futile without implementation
DOI: https://doi.org/10.1093/eurheartj/eht551
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-154283
Journal Article
Published Version
Originally published at:
Gielen, S; Landmesser, U (2014). The Year in Cardiology 2013: cardiovascular disease prevention.
European Heart Journal, 35(5):307-312.
DOI: https://doi.org/10.1093/eurheartj/eht551
CURRENTOPINION
The Year in Cardiology
The Year in Cardiology 2013: cardiovascular
disease prevention
S. Gielen1* and U. Landmesser2*
1Department of Internal Medicine III, Martin-Luther-University Halle/Wittenberg, University Hospital, Ernst-Grube-Str. 40, 06120 Halle/Saale, Germany; and 2Department of Cardiology,
University of Zurich – Heart Center, Ra¨mistrasse 100, 8091 Zurich, Switzerland
Received 28 October 2013; revised 24 November 2013; accepted 28 November 2013
The decline in cardiovascular mortality in Europe by nearly 50% over the last three decades resulted in particular from improved risk factor
control and prevention interventions in addition to improved treatment. This review provides an overview of key studies in epidemiology, hyper-
tension control, lipidology, diabetology, and lifestyle changes published in 2013. EXAMINE in diabetology and AIM-High and HPS-2-THRIVE in
lipidology failed to demonstrate an event reduction. According to EUROASPIRE IV clinical implementation of secondary prevention treatments is
still suboptimal. The 2013 study highlights in prevention prove the dynamic progress of knowledge in the field;, however, knowledge alone is futile
without implementation.
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Introduction
Despite the significant decline in cardiovascular mortality in Europe by
nearly50%over the last threedecades1 cardiovasculardiseases remain
the primary cause of death accounting for 42% of fatalities in men and
52% of deaths in women.2 They cause over 4 million deaths in Europe
annually (17.3 million worldwide) of which 1.5 million are premature
below the age of 75.3,4 The total financial burden is estimated to be
190 billion Euros per year. It is therefore encouraging to see that pre-
vention is entering a new era not just in scientific knowledge but also in
implementation in health-care systems. During the last years the epi-
demiological, clinical, and experimental data accumulated in research
in prevention have finally influenced political decisions at the highest
level. In September 2011 representatives from 113 United Nation
Member States met at a UN High Level Meeting in New York to
signacommondeclarationmaking thefightagainstnon-communicable
diseases (NCDs) a top priority in health care. The political goal is to
reduce the mortality from NCDs by 25% by the year 2025. However,
not all NCDs are equally responsive to preventive interventions. It
is estimated that a 40% reduction in cardiovascular disease (CVD)
mortality is needed by 2025 in order to come anywhere near the
global goal of 25% reduction in total NCD mortality. The rapidly
expanding knowledge in prevention research provides the scientific
evidence to achieve these ambitious goals. In the present article we
summarize some of the interestingnovel insights in the fieldof cardio-
vascular prevention published in the year 2013.
Epidemiological studies in
prevention
Current trends in cardiovascular risk
factor control
PURE Study
The PURE Study is one of the few truly global epidemiological studies
in CVD prevention. The total number of 154 000 people from 628
communities in 17 countries represent not only the high-income
countries in North America and in Europe but also the middle- and
low-income contries of the world, including Brazil, Argentina, Malay-
sia, andChina asmiddle-incomecountries, and India, Pakistan, Bangla-
desh, Zimbabwe as low-income contries. Prof. Yusuf and his team
aimed to determine the prevalence and mortality of CVD in different
socioeconomic environments by long-term follow-up (3.8 years) and
regular contacts to ascertain mortality from participants and family
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members.The INTERHEARTrisk score (IRS) comprisingdataonage,
sex, smoking, diabetes, hypertension, family history of heart disease,
waist-hip-ratio, psychosocial status, diet, and physical activity was cal-
culated for each participant. Not surprisingly the IRS was highest in
the high-income countries (13), lower in the middle-income coun-
tries (10–11), and lowest in the low-income countries (7–9).
However, the gradient for fatal CVD incidence was in the opposite
direction, indicating that the low-income countries pay a higher
death toll per IRS score because their health systems are not able
to treat risk factors and disease manifestations as effectively as in
the high-income countries. The authors conclude that the PURE
study documents the ‘Need for stronger and efficient health-care
systems for CVD prevention and treatment globally’.5 –7
EUROASPIRE-IV
The fourth iteration of this landmark study gives a unique insight into
current trends of control of cardiovascular risk factors and the use of
drugs in patients with coronary disease in Europe. The study included
.100 sites in.25 European countries. Despite a high prevalence of
statin, aspirin, and angiotensin-converting enzyme inhibtor use, 75%
of patients with coronary disease are not at the goal for LDL cho-
lesterol (,1.8 mmol/L) and 45% of patients are not at the goal for
the blood pressure (,140/90 mmHg, for patients with diabetes
,140/80 mmHg). These observations suggest further important
opportunities in improving cardiovascular preventive measures in
these patients in the future, including novel agents to target LDL
cholesterol, such as proprotein convertase subtilisin/kexin type 9
(PCSK-9) or cholesterylester transfer protein (CETP) inhibition
that are currently examined in large clinical outcome trial pro-
grammes. Moreover, in EUROASPIRE-IV the prevalence of obesity
and type-2 diabetes is increasing in patients with CAD when com-
paredwith the previous EUROASPIRE III study, suggesting that imple-
mentation of life style changes needs to be more intensely pursued.
Heart-healthy lifestyle adds years in people
without risk factors
Leading a heart-healthy lifestyle is not only important for people with
a clear cardiovascular risk profile. In a substudy of the NHANES III
follow-up Mortality Survey the authors were able to show that
even among adults without common cardiovascular risk factors
such as elevated cholesterol (low-density lipoprotein, LDL,
cholesterol .130 mg/dl), inflammation (C-reactive protein, CRP,
.3.0 mg/L, or hypertension (blood pressure .140/90 mmHg)
neglecting healthy lifestyle habits significantly increased all-cause
mortality. People who practised 0–1 healthy habits had a nearly five-
fold increase in all-cause mortality when compared with those who
observed all 5 healthy habits [heart rate (HR) 4.89, 95% confidence
interval 1.49–16.0].8
Heart rate in the general population: an
indicator of cardiovascular risk?
Since the publication of the SHIFT study it is common medical sense
that high HRs are predictive of increased mortality in heart failure
patients. But is the same true in the general population and does
average HR change over time? These two questions were at the
heart of a large population-based study led by Plichart who analysed
226 288 consecutive participants (141 533 men and 84 755 women)
aged 44.7+12.7 years who had a free standard health check up
between 1992 and 2007. During the 15-year study period the
crude mean HR decreased from 68.9+10.4 to 63.7+9.0 b.p.m.
in men and from 72.2+10.3 to 65.2+9.0 b.p.m. in women; P,
0.001 for both) independent from risk factor changes. On multivari-
ate analysis, higher HR (≥80 vs. ,60 b.p.m.) was associated with
111% higher 5-year mortality rate in men and a 58% increased
5-year mortality in women. It may be worthwhile to study if elevated
restingHR shouldbe includedas independent risk factor in cardiovas-
cular risk assessments (Figures 1 and 2).9
Clinical intervention studies in
prevention
Hypertension: obesity and selection of
antihypertensive medication
In previous studies of antihypertensive drugs in high-risk patients a
paradoxically higher cardiovascular event rate has been observed
in normal weight vs. obese patients. This paradox was now resolved
in a pre-specified analysis of the Avoiding Cardiovascular Events through
Combination Therapy in Patients Living with Systolic Hypertension
(ACCOMPLISH) trial, in which the patient cohort was subdivided
into three groups: obese [body mass index (BMI) ≥ 30, n ¼ 5709],
overweight (≥25–,30, n ¼ 4157), and normal weight (,25, n ¼
1616) individuals. In patients allocated to a combination of benazepril
and hydrochlorothiazide, the primary endpoint (per 1000 patient-
years) was 30.7 in normal weight, 21.9 in overweight, and 18.2 in
obese patients (P ¼ 0.0034). This obesity-related gradient of cardio-
vascular events was absent in those allocated benazepril and amlodi-
pine. The authors hypothesize thathypertension mechanisms maybe
different in normal weight and obese patients and therefore thiazide-
based treatment provides less cardiovascular protection in normal
weight than in obesity but amlodipine-based therapy is equally effect-
ive across BMI subgroups and thus may offer superior cardiovascular
protection in non-obese hypertension.10 Three-year follow-up data
of an open-label study of renal denervation (RDN) with radiofre-
quency ablation suggest that in patients with treatment-resistant
hypertension RDN may result in persistent changes in blood pres-
sure after 3 years (as observed in 88 patients after 36 months).11
Lipidology: high-density lipoprotein
cholesterol: not an easy target for
cardiovascular preventive therapies?
The cardiovascular preventive efficacy of statin therapy is broadly
supported by clinical trials, and a meta-analysis of the cholesterol
treatment trialists (CTT) has shown that when compared with less
intensive statin regimens, more intensive statin regimens produced
a significant 15% further reduction in major vascular events, support-
ing intensive statin therapy in patients at high cardiovascular risk.12
Another interesting meta-analysis of this group has now suggested
that in individuals with a lower risk of vascular disease (i.e. 5-year
risk of major vascular events lower than 10%), each 1 mmol/L reduc-
tion in LDL cholesterol by statin therapy produced an absolute
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reduction in major vascularevents of11 per 1000 over5 years, sup-
porting earlier use of statin therapy in these individuals.13
An important question is whether addition of other lipid-
modulating agents to statin therapy can further reduce cardiovas-
cular events. Addition of niacin to statin therapy, which can also
moderately raise HDL cholesterol serum levels, has now been
examined in high-risk patients in the AIM-High and HPS-2-THRIVE
study.14 Both clinical trials failed to demonstrate a further reduc-
tion of cardiovascular events by addition of niacin therapy, that,
however, caused several adverse effects.14 Inhibition of the
secretory phospholipase A2 by varespladip in addition to statin
therapy failed to reduce cardiovascular events in patients with a
recent ACS and increased the risk of myocardial infarction.15 More-
over, CETP-inhibition by dalcetrapib leading to a moderate
increase of HDL cholesterol levels did not improve endothelial
function16 and failed to reduce cardiovascular events in patients
after an ACS.17 The difficult search for an effective ‘partner’ of
statins in lipid-targeted prevention of vascular events therefore
goes on.18 The IMPROVE-IT study currently examines the effect
of ezetimibe on cardiovascular events in addition to statin
Figure 1 Trends in the mean resting heart rate from 1992 to 2007 in men and women. Fitted curves are adjusted for age, body mass index, blood
pressure≥140/90 mmHg, smoking status, glycaemia≥7 mmol/L, total serum cholesterol, physical activity, and cardiovascular treatment. Reprinted
from ref. 9.
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therapy. Besides CETP inhibitors with potent LDL cholesterol low-
ering effects, PCSK9 inhibition by monoclonal antibodies in add-
ition to statin therapy has now entered large-scale clinical trial
programmes. Moreover, PCSK9 inhibition by means of RNA inter-
ference has recently been shown in a phase-1 study to be a poten-
tially safe mechanism to reduce LDL cholesterol concentration in
humans.19
The recently published largest genetic association study of blood
lipid levels by the Global Lipids Genetics Consortium identified a
large number of loci and many candidate genes that may give novel
insights into lipid biology. Moreover, it was suggested that in univari-
ate analyses, genetic effectson LDLcholesterol and triglyceride levels
predicted an association with coronary disease, but HDL cholesterol
levels did not.20 Furthermore, HDL cholesterol-associated variants
had markedly different effects on lipid subphenotypes (such as
sphingomyelin), suggesting that functional groupings of HDL
cholesterol-associated variants may have to be performed in future
studies.20
Figure2 Five-year adjusted survival rates according to heart rate categories in both men and women. Adjustment wasmade for the same variables
as in Figure 1. Reprinted from ref. 9.
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Diabetes and obesity:
First large-scale cardiovascular outcome data for
incretine-based treatment of diabetes
Several studies in patients with diabetes mellitus have demonstrated
that improved glucose control reduces microvascular complications.
However, uncertainty remains whether any glucose-lowering strat-
egy is safe from a CV standpoint or can lower macrovascular compli-
cations, such as myocardial infarction, stroke, or CV death. Two
large-scale clinical trials have now examined the effects of dipeptidyl
peptidase 4 (DPP-4) inhibition by saxagliptin and alogliptin to lower
glucose on cardiovascular events. Dipeptidyl peptidase 4 inhibition
with saxagliptin did not increase or decrease the rate of ischaemic
cardiovascular events, although glycaemic control was improved.21
In the EXAMINE trial including patients with type 2 diabetes who
had had a recent acute coronary syndrome, the rates of major
adverse cardiovascular events were not decreased or increased
with the DPP-4 inhibitor alogliptin when compared with placebo.22
These studies suggest that other approaches are necessary to
reduce cardiovascular risk in patients with diabetes.
Lifestyle change difficult to maintain in long-term studies
It is well-established that obesity and diabetes are associated with an
increased risk for future cardiovascular events. Intuitively, one would
conclude that weight reduction should therefore reduce cardiovas-
cular events in obese diabetics. Surprisingly, the long-term effects
of weight loss on CVD remain unknown. In the Look-AHEAD
Study the investigators therefore randomly assigned 5145 over-
weight or obese patients with type 2 diabetes to participate in an in-
tensive lifestyle intervention that promoted weight loss through
decreased caloric intake and increased physical activity (intervention
group) or to receive diabetes support and education (control group).
Although weight loss was greater in the intervention group (8.6 vs.
0.7% at1 year; 6.0 vs. 3.5% at studyend) and reduced glycated haemo-
globin other cardiovascular risk factors, except for
low-density-lipoprotein cholesterol levels the primary outcome
(death from cardiovascular causes, non-fatal myocardial infarction,
non-fatal stroke, or hospitalization for angina) was not significantly
reduced (1.83 and 1.92 events per 100 person-years, respectively;
HR 0.95; 0.83–1.09; P ¼ 0.51).23 The study reminds us that there
are no simple solutions in metabolic syndrome. A key problem in
the intervention group was that a large weight reduction after 1
year was followed by weight regain in the remaining study period.
Likewise, physical fitness improved significantly at 12 months and
deteriorated thereafter. These observations imply that the adher-
ence to the lifestyle intervention was optimal in Year 1 and decreased
thereafter. Future lifestyle interventions need to address the long-
term intervention compliance as a key problem—possibly using tele-
medicine or telenursing as tools.
Exercise training: non-responders have
impaired chronotropic competence
Endurance training has proven beneficial effects including chronic
heart failure patients, such as increase of exercise capacity, quality
of life, reduced hospitalization, and most likely reduced mortality
(based on meta-analyses24). However, rehabilitation specialists all
know patients who do not show the expected positive outcomes
and the search for predictors for being a non-responder has not
yet been very successful. In their article in the European Journal of Pre-
ventive Cardiology Schmid et al. from Berne, Switzerland, assessed 120
consecutive CHF patients with sinus rhythm (peak VO2 17.3+
5.1 mL/min/kg) who participated in a 3-month outpatient cardiac re-
habilitation programme for non-responders (definedas subjects who
failed to improve peak VO2 by .5%, work load by .10%, or VE/
VCO2 slope by .5%). Multivariate analysis and receiver operating
characteristic (ROC) analysis identified non-reponders with
,30 b.p.m. for HR reserve, ,6 b.p.m. for HR recovery, and
,101 b.p.m. for peak HR. In conclusion, an adequate chronotropic
response to exercise seems to be a prerequisite for deriving a clinical
benefit from exercise training in chronic heart failure.25
Future research perspectives
Research in CVD prevention has traditionally focused on epidemio-
logical research in time trends of risk factor and disease prevalence,
on clinical studies in pharmaceutical risk factor control (most
notably in diabetes, blood pressure, and lipid control), and experi-
mental research to better understand the vascular biology of athero-
genesis. However, by just telling people how to lead a heart-healthy
life and by using drugs to control hypertension, diabetes, and hyper-
lipidaemia we did not succeed in winning the battle against CVD. We
know disease mechanisms and have potent drugs, however, patients
are too frequently not willing to change their unhealthy lifestyle and
their physicians invest more time and money in acute care of compli-
cations than in aggressive disease prevention. Several key perspec-
tives for future research in prevention emerge from this situation:
† We need well-designed studies comparing not a single drug treat-
ment but an entire prevention strategy to each other. There is
nearly no evidence on how to best educate and motivate patients
tochange their lifestyle and tomaintain regularphysical activity and
healthy eating habits in the long run. Optimizing communication
and motivation is key to influencing lifestyles.
† Efforts in individual preventioneducationwill be futile if notbacked
up by coherent legislative frameworks which reward healthy life-
styles and make risky lifestyle behaviours unattractive. There is
clear evidence from epidemiological studies from which laws
and taxation mechanisms work3—the challenge is to implement
them.
† Physicians follow the priorities of their health-care systems. If
reimbursement for preventive activities is not adaequate there
may be too little motivation to invest time and effort in prevention.
Pilot studies are needed in which reimbursement mechanisms or
other incentives work best in motivating physicians to focus on
prevention and to shift from a procedure centred to an outcome-
focused performance.
In a recent article published simulaneously in the European Heart
Journal, Circulation, JACC and the World Heart Journal the large cardio-
vascular societies called for action to achieve the 25 by 25 goal. The
title of the article was ‘Our time: a call to save preventable death from
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CVD’ and timely it is indeed to make prevention of CVD the health
priority that it should be.26
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